Docetaxel cytotoxicity is enhanced by inhibition of the Raf/MEK/ERK signal transduction pathway

Cancer Biol Ther. Nov-Dec 2003;2(6):677-8.
No abstract available

Publication types

  • Research Support, U.S. Gov't, P.H.S.
  • Comment

MeSH terms

  • Antineoplastic Agents, Phytogenic / toxicity*
  • Breast Neoplasms / metabolism
  • Breast Neoplasms / pathology
  • Butadienes / pharmacology
  • Cell Division / drug effects
  • Cell Line, Tumor
  • Docetaxel
  • Drug Administration Schedule
  • Drug Synergism
  • Drug Therapy, Combination
  • Enzyme Inhibitors / pharmacology
  • Female
  • Humans
  • Mitogen-Activated Protein Kinases / antagonists & inhibitors*
  • Nitriles / pharmacology
  • Phosphorylation / drug effects
  • Protein-Serine-Threonine Kinases / drug effects
  • Proto-Oncogene Proteins / drug effects
  • Proto-Oncogene Proteins c-akt
  • Proto-Oncogene Proteins c-raf / antagonists & inhibitors*
  • Signal Transduction*
  • Taxoids / toxicity*
  • Time Factors

Substances

  • Antineoplastic Agents, Phytogenic
  • Butadienes
  • Enzyme Inhibitors
  • Nitriles
  • Proto-Oncogene Proteins
  • Taxoids
  • U 0126
  • Docetaxel
  • Protein-Serine-Threonine Kinases
  • Proto-Oncogene Proteins c-akt
  • Proto-Oncogene Proteins c-raf
  • Mitogen-Activated Protein Kinases